Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01035229
Registration number
NCT01035229
Ethics application status
Date submitted
17/12/2009
Date registered
18/12/2009
Date last updated
22/09/2016
Titles & IDs
Public title
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Query!
Scientific title
A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study
Query!
Secondary ID [1]
0
0
2009-010196-25
Query!
Secondary ID [2]
0
0
CRAD001O2301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EVOLVE-1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Liver
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Everolimus
Treatment: Drugs - Everolimus Placebo
Other interventions - Best Supportive Care (BSC)
Experimental: Everolimus + Best Supportice Care (BSC) - Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
Placebo Comparator: Placebo + Best Supportive Care - Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
Treatment: Drugs: Everolimus
Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
Treatment: Drugs: Everolimus Placebo
Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
Other interventions: Best Supportive Care (BSC)
BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance.
Query!
Timepoint [1]
0
0
When 454 OS events were observed
Query!
Secondary outcome [1]
0
0
Time to Tumor Progression (TTP)
Query!
Assessment method [1]
0
0
TTP was defined as the time from the date of randomization to the date of the first documented radiologic confirmation of disease progression. Since the study did not meet the primary objective, TTP was not formally tested.
Query!
Timepoint [1]
0
0
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Disease Control Rate (DCR)
Query!
Assessment method [2]
0
0
DCR is defined as the proportion of participants with a best objective response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST. The BOR was the best response recorded from the start of the treatment until disease progression. CR is disappearance of all target lesions; PR is at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD is neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is at least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.
Query!
Timepoint [2]
0
0
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
Query!
Secondary outcome [3]
0
0
Time to Definitive Deterioration of ECOG Performance Score (PS) Score
Query!
Assessment method [3]
0
0
Change in Eastern Cooperative Oncology Group (ECOG) were assessed by time to definitive performance status deterioration by at least one category on the ECOG scale. Deterioration was considered definitive if no improvement in the ECOG PS was observed at a subsequent measurement. ECOG PS: 0=Fully active, able to carry on all pre-disease performance without restriction, 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; 5=Dead
Query!
Timepoint [3]
0
0
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
Query!
Secondary outcome [4]
0
0
Time to Definitive Deterioration of EORTC QLQ-C30 Scores
Query!
Assessment method [4]
0
0
The primary quality of life endpoint was the time to definitive 5% deterioration from baseline in the global health status/quality of life scale of the EORTC QLQ-C30 questionnaire. Definitive deterioration by at least 5% is defined as a decrease in score by at least 5% compared to baseline, with no later observed increase above this threshold. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Query!
Timepoint [4]
0
0
Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
Query!
Secondary outcome [5]
0
0
Pharmacokinetics Assessments - Cmin
Query!
Assessment method [5]
0
0
Cmin is the pre-dose blood concentration at steady-state (ng/mL). Pre-dose (Cmin) blood samples were collected from all patients in both arms at Visit 3. Steady-state for the Cmin sample was defined as continuous administration of the same dose in the last 4 days prior to the collection of the Cmin sample. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid pre-dose (Cmin) everolimus samples were included in the analysis.
Query!
Timepoint [5]
0
0
Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
Query!
Secondary outcome [6]
0
0
Pharmacokinetics Assessments - Cmax
Query!
Assessment method [6]
0
0
Cmax is the maximum (peak) blood drug concentration after dose administration (ng/mL) calculated as the maximum of C1h and C2h. C1h was 1 hour post-dose blood concentration (ng/mL) and C2h was 2 hour post-dose blood concentration (ng/mL). C1h and C2h post-dose samples were collected from all patients in both arms at Visit 3. Steady-state for the C1h and C2h samples was defined as continuous administration of the same dose in the previous 4 days and the day on which the C1h and C2h samples were collected. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid C1h and C2h everolimus samples were included in the analysis.
Query!
Timepoint [6]
0
0
Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
Query!
Eligibility
Key inclusion criteria
- Advanced liver cancer
- Prior systemic treatment with sorafenib for advanced HCC and for whom their disease
progressed during or after sorafenib treatment, or were intolerant to sorafenib
treatment. Specifically, this can be defined as:
- Documented radiological confirmation (radiology scans or report) of disease
progression during or after sorafenib treatment
- Intolerance to sorafenib (at any dose and/or duration) is defined as documented
sorafenib-related grade 3 or 4 adverse events that led to sorafenib
discontinuation.
NOTE:
- Sorafenib must be the last antineoplastic treatment before randomization
- Prior local and/or hormonal therapy (e.g., tamoxifen) before sorafenib is allowed
- One systemic chemotherapy regimen for advanced HCC is allowed before sorafenib
treatment
- ECOG performance status of = 2
- Child-Pugh A
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Active bleeding during the last 28 days
- Prior therapy with mTOR inhibitors
- Prior liver or other organ transplantation which mandates systemic immunosuppression
Other protocol-defined inclusion/exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
546
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Kogarah
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Westmead
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Heidelberg
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Hawaii
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nevada
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oregon
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Washington
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Graz
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Innsbruck
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Wien
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bruxelles
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Edegem
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Leuven
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Ontario
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Quebec
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Jiangsu
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Shanxi
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Sichuan
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Zhejiang
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Beijing
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Guangzhou
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Amiens cedex 1
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Avignon Cedex
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Bordeaux Cedex
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Caen Cedex9
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Chambray-lès-Tours
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Clermont Ferrand cedex 1
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Clichy
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Dijon
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Lille Cedex
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Lyon Cedex 04
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Marseille Cédex 5
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Montpellier Cedex 5
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Nantes Cedex 1
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Nice Cedex 3
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Reims
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Rouen Cedex
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
St Priest en Jarez Cedex
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Strasbourg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Baden-Württemberg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Berlin
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Essen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Esslingen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Frankfurt
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Goettingen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Hamburg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Hannover
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Leipzig
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Muenchen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Würzburg
Query!
Country [58]
0
0
Greece
Query!
State/province [58]
0
0
GR
Query!
Country [59]
0
0
Greece
Query!
State/province [59]
0
0
Thessaloniki
Query!
Country [60]
0
0
Hong Kong
Query!
State/province [60]
0
0
Hong Kong
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Budapest
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Debrecen
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Szeged
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Szombathely
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Petach Tikva
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Ramat Gan
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
BN
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
BO
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
FG
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
MI
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
MO
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
PA
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
PD
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
PN
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
PV
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
RM
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Frattamaggiore
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Napoli
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Aichi
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Chiba
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Ehime
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Fukuoka
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Gifu
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Ishikawa
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Kanagawa
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Kumamoto
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Miyagi
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Osaka
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Tokyo
Query!
Country [90]
0
0
Korea, Republic of
Query!
State/province [90]
0
0
Korea
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Andalucia
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Barcelona
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Catalunya
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Navarra
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Madrid
Query!
Country [96]
0
0
Taiwan
Query!
State/province [96]
0
0
Taiwan, ROC
Query!
Country [97]
0
0
Taiwan
Query!
State/province [97]
0
0
Lin-Kou
Query!
Country [98]
0
0
Taiwan
Query!
State/province [98]
0
0
Liouying Township
Query!
Country [99]
0
0
Taiwan
Query!
State/province [99]
0
0
Niaosong Township
Query!
Country [100]
0
0
Taiwan
Query!
State/province [100]
0
0
Taichung
Query!
Country [101]
0
0
Taiwan
Query!
State/province [101]
0
0
Tainan
Query!
Country [102]
0
0
Taiwan
Query!
State/province [102]
0
0
Taipei
Query!
Country [103]
0
0
Thailand
Query!
State/province [103]
0
0
Bangkok
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC)
to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after
sorafenib treatment or who are intolerant to sorafenib.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01035229
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01035229
Download to PDF